Inhibition of Poly(ADP-ribose)polymerase impairs Epstein Barr Virus lytic cycle progression
2007
How a Drug Affects the Epstein-Barr Virus Cycle
publication
Evidence: moderate
Author Information
Author(s): Mattiussi Stefania, Tempera Italo, Matusali Giulia, Mearini Giulia, Lenti Luisa, Fratarcangeli Silvia, Mosca Luciana, D'Erme Maria, Mattia Elena
Primary Institution: University 'Sapienza'
Hypothesis
Does inhibiting PARP-1 affect the lytic cycle of Epstein-Barr Virus?
Conclusion
Inhibiting PARP-1 impairs the progression of the Epstein-Barr Virus lytic cycle and reduces viral particle release.
Supporting Evidence
- Inhibition of PARP-1 reduced cell damage and apoptosis in Raji cells.
- 3-ABA treatment increased levels of latent viral proteins LMP1 and EBNA2.
- Viral DNA release was significantly lower in the presence of 3-ABA.
Takeaway
The study shows that a drug can help stop the Epstein-Barr Virus from spreading by affecting how it grows.
Methodology
The study involved treating Burkitt lymphoma-derived Raji and Jijoye cells with a PARP-1 inhibitor and analyzing the effects on EBV lytic cycle activation.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website